Skip to main content
PMC home page
Indian Heart Journal logoLink to Indian Heart Journal
. 2012 Jan;64(1):54–59. doi: 10.1016/S0019-4832(12)60012-1

Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor—a long continuing journey

Upendra Kaul a,*, Aijaz H Mansoor b
PMCID: PMC3861274  PMID: 22572427

Abstract

Platelet aggregation plays a central role in the pathogenesis of atherothrombosis. Platelet adenosine diphosphate (ADP) receptor antagonists (ticlopidine, clopidogrel, prasugrel, and ticagrelor) are a major advance in the treatment of atherothrombotic diseases, especially acute coronary syndromes (ACS). Ticlopidine was the first thienopyridine introduced into clinical practice, but its potentially serious haematological side-effects limited its use and it was quickly eclipsed by clopidogrel. Clinical trials established aspirin plus clopidogrel as the standard dual anti-platelet therapy in patients with ACS and patients undergoing percutaneous coronary intervention (PCI) with stenting. Clopidogrel was found to have pharmacokinetic and pharmacodynamic limitations. Prasugrel is the next approved thienopyridine that has shown superior efficacy in ACS patients undergoing PCI in comparison to clopidogrel, although at the cost of a higher bleeding risk. Ticagrelor is the latest non-thienopyridine ADP receptor blocker that is potent, effective, reversible, and relatively safer as compared to clopidogrel.

Both prasugrel and ticagrelor are more potent than clopidogrel. The data so far suggests that ticagrelor has a wider applicability in usage in patients with ACS as compared to prasugrel. Prasugrel however seems to be better tolerated. Search is on for newer more potent but safer anti-platelet agents.

Keywords: Anti-platelet therapy, Prasugrel, Ticagrelor

References

  • 1.Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio Della Ticlopidina nell'Angina Instabile Group. Circulation. 1990;82:17–26. doi: 10.1161/01.cir.82.1.17. [DOI] [PubMed] [Google Scholar]
  • 2.Goods CM, al-Shaibi KF, Liu MW. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol. 1996;78:1042–1044. doi: 10.1016/s0002-9149(96)00532-2. [DOI] [PubMed] [Google Scholar]
  • 3.Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) Circulation. 2000;102:624–629. doi: 10.1161/01.cir.102.6.624. [DOI] [PubMed] [Google Scholar]
  • 4.CAPRIE Steering Committee A randomised blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet. 1996;348:1329–1339. doi: 10.1016/s0140-6736(96)09457-3. [DOI] [PubMed] [Google Scholar]
  • 5.Yusuf S, Zhao F, Mehta SR. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. doi: 10.1056/NEJMoa010746. [DOI] [PubMed] [Google Scholar]
  • 6.Mehta SR, Yusuf S, Peters RJ. Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–533. doi: 10.1016/s0140-6736(01)05701-4. [DOI] [PubMed] [Google Scholar]
  • 7.Sabatine MS, Cannon CP, Gibson CM. Clopidogrel as adjunctive reperfusion therapy (CLARITY)-thrombolysis in myocardial infarction (TIMI) 28 investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 Investigators. N Engl J Med. 2005;352:1179–1189. doi: 10.1056/NEJMoa050522. [DOI] [PubMed] [Google Scholar]
  • 8.Chen ZM, Jiang LX, Chen YP. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–1621. doi: 10.1016/S0140-6736(05)67660-X. [DOI] [PubMed] [Google Scholar]
  • 9.Dangas G, Mehran R, Guagliumi G. On behalf of the HORIZONS-AMI trial investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2009;54:1438–1446. doi: 10.1016/j.jacc.2009.06.021. [DOI] [PubMed] [Google Scholar]
  • 10.The CURRENT-OASIS 7 Investigators Dose comparisons of clopidogrel andaspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–942. doi: 10.1056/NEJMoa0909475. [DOI] [PubMed] [Google Scholar]
  • 11.Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pre-treatment platelet reactivity. Circulation. 2003;107:2908–2913. doi: 10.1161/01.CIR.0000072771.11429.83. [DOI] [PubMed] [Google Scholar]
  • 12.Mega JL, Close SL, Wiviott SD. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362. doi: 10.1056/NEJMoa0809171. [DOI] [PubMed] [Google Scholar]
  • 13.Frere C, Cuisset T, Morange PE. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008;101:1088–1093. doi: 10.1016/j.amjcard.2007.11.065. [DOI] [PubMed] [Google Scholar]
  • 14.Angiolillo DJ, Fernandez-Ortix A, Bernanrdo E. Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol. 2007;49:1505–1516. doi: 10.1016/j.jacc.2006.11.044. [DOI] [PubMed] [Google Scholar]
  • 15.Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004;109:3064–3067. doi: 10.1161/01.CIR.0000134701.40946.30. [DOI] [PubMed] [Google Scholar]
  • 16.Wallentin L, Varenhorst C, James S. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21–30. doi: 10.1093/eurheartj/ehm545. [DOI] [PubMed] [Google Scholar]
  • 17.Wiviott SD, Braunwald E, McCabe CH. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015. doi: 10.1056/NEJMoa0706482. [DOI] [PubMed] [Google Scholar]
  • 18.Bhatt DL. Prasugrel in Clinical Practice. N Engl J Med. 2009;361:940–942. doi: 10.1056/NEJMp0806848. [DOI] [PubMed] [Google Scholar]
  • 19.Curfman GD, Morrissey S, Jarcho JA, Drazen JM. Drug-eluting coronary stents-promise and uncertainty. N Engl J Med. 2007;356:1059–1060. doi: 10.1056/NEJMe068306. [DOI] [PubMed] [Google Scholar]
  • 20.Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008;371:2134–2143. doi: 10.1016/S0140-6736(08)60922-8. [Erratum, Lancet 2008; 372:536.] [DOI] [PubMed] [Google Scholar]
  • 21.Storey RF, Husted S, Harrington RA. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852–1856. doi: 10.1016/j.jacc.2007.07.058. [DOI] [PubMed] [Google Scholar]
  • 22.Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–1047. doi: 10.1093/eurheartj/ehi754. [DOI] [PubMed] [Google Scholar]
  • 23.Wallentin L, Becker RC, Budaj A, for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. doi: 10.1056/NEJMoa0904327. [DOI] [PubMed] [Google Scholar]
  • 24.Cannon C, Harrington R, James S, the PLATelet inhibition and patient Outcomes (PLATO) investigators Ticagrelor compared with clopidogrel in acute coronary syndromes patients with a planned invasive strategy (PLATO): a randomized double-blind study. Lancet. 2010;375:283–293. doi: 10.1016/S0140-6736(09)62191-7. [DOI] [PubMed] [Google Scholar]
  • 25.Schömig A. Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N Engl J Med. 2009:361. doi: 10.1056/NEJMe0906549. [DOI] [PubMed] [Google Scholar]
  • 26.Ticagrelor versus clopidogrel in patients with acute coronary syndrome intended for non invasive management: sub study from prospective randomized platelet inhibition and outcomes (PLATO) trial.
  • 27.Held C, Asenblad N, Bassand JP. Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing coronary artery bypass surgery: results from PLATO trial. L Am Coll Cardiol. 2011;57:672–684. doi: 10.1016/j.jacc.2010.10.029. [DOI] [PubMed] [Google Scholar]
  • 28.Levine GN, Bates ER, Blankenship JC. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574–e651. doi: 10.1161/CIR.0b013e31823ba622. [DOI] [PubMed] [Google Scholar]
  • 29.Hamm CW, Bassand JP, Agewall S. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2011 doi: 10.1093/eurheartj/ehr236. [DOI] [PubMed] [Google Scholar]

Articles from Indian Heart Journal are provided here courtesy of Elsevier

RESOURCES